Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

SARS-CoV-2 infection among patients with systemic autoimmune diseases

OBJECTIVES: This study aimed to evaluate the prevalence of clinically overt SARS-CoV-2 infection (COVID-19) among patients with systemic autoimmune diseases residing in Tuscany, and to compare it with that observed in the general Tuscan population

METHODS: In this cross-sectional study, Tuscan outpatients with systemic autoimmune diseases followed at a tertiary referral centre were telephonically interviewed between April 1st-14th 2020 to collect demographic and clinical data, information on ongoing immunomodulating/immunosuppressive treatments, and on the presence of symptoms suspected of SARS-CoV-2 or of a confirmed infection

RESULTS: 458 patients were interviewed [74% female, median age 56 years (IQR 43-68)]; 56% of them were receiving corticosteroids, 44% traditional disease-modifying anti-rheumatic drugs (DMARDs), of whom 23% hydroxychloroquine, 5% colchicine, while 41% were on biologic DMARDs (of whom 9% on tocilizumab). Thirteen patients reported symptoms suggesting SARS-CoV-2 infection. Of them, 7 had undergone nasopharyngeal swab and only one was positive and developed severe SARS-CoV-2 complications. Within our cohort, the prevalence of SARS-CoV-2 infection was therefore 0.22% (0.01-1.21%), comparable to that observed in the general population of Tuscany [0.20% (0.20-0.21%), p = .597]

CONCLUSIONS: Patients with systemic autoimmune diseases do not seem to carry an increased risk of SARS- CoV-2 infection as compared to the general population

Year of Publication: 2020
Contained in: Autoimmunity reviews Vol. 19, No. 7 (2020), p. 102575
All journal articles: Search for all articles in this journal
Language: English
Contributors: Emmi, Giacomo | Author
Bettiol, Alessandra
Mattioli, Irene
Silvestri, Elena
Di Scala, Gerardo
Urban, Maria Letizia
Vaglio, Augusto
Prisco, Domenico
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: 4QWG6N8QKH
COVID-19
I031V2H011
Immunosuppressants
Journal Article
Review
SML2Y3J35T
Systemic autoimmune diseases
Tocilizumab
tocilizumab
Additional Keywords: Adrenal Cortex Hormones
Adult
Aged
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Autoimmune Diseases
Betacoronavirus
Colchicine
Coronavirus Infections
Cross-Sectional Studies
Female
Humans
Hydroxychloroquine
Italy
Male
Middle Aged
Pandemics
Pneumonia, Viral
ISSN: 1873-0183
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 10.06.2020
Date Revised 10.06.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32376395
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1016/j.autrev.2020.102575
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 05110nma a2201093 c 4500
001 NLM310461324
003 DE-601
005 20200611213828.0
007 cr uuu---uuuuu
008 200507s2020 000 0 eng d
024 7 |a 10.1016/j.autrev.2020.102575  |2 doi 
028 5 2 |a pubmed20n1228.xml 
035 |a S1568-9972(20)30137-3 
035 |a (DE-599)NLM32376395 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Emmi, Giacomo 
245 1 0 |a SARS-CoV-2 infection among patients with systemic autoimmune diseases  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 10.06.2020 
500 |a Date Revised 10.06.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2020 Elsevier B.V. All rights reserved. 
520 |a OBJECTIVES: This study aimed to evaluate the prevalence of clinically overt SARS-CoV-2 infection (COVID-19) among patients with systemic autoimmune diseases residing in Tuscany, and to compare it with that observed in the general Tuscan population 
520 |a METHODS: In this cross-sectional study, Tuscan outpatients with systemic autoimmune diseases followed at a tertiary referral centre were telephonically interviewed between April 1st-14th 2020 to collect demographic and clinical data, information on ongoing immunomodulating/immunosuppressive treatments, and on the presence of symptoms suspected of SARS-CoV-2 or of a confirmed infection 
520 |a RESULTS: 458 patients were interviewed [74% female, median age 56 years (IQR 43-68)]; 56% of them were receiving corticosteroids, 44% traditional disease-modifying anti-rheumatic drugs (DMARDs), of whom 23% hydroxychloroquine, 5% colchicine, while 41% were on biologic DMARDs (of whom 9% on tocilizumab). Thirteen patients reported symptoms suggesting SARS-CoV-2 infection. Of them, 7 had undergone nasopharyngeal swab and only one was positive and developed severe SARS-CoV-2 complications. Within our cohort, the prevalence of SARS-CoV-2 infection was therefore 0.22% (0.01-1.21%), comparable to that observed in the general population of Tuscany [0.20% (0.20-0.21%), p = .597] 
520 |a CONCLUSIONS: Patients with systemic autoimmune diseases do not seem to carry an increased risk of SARS- CoV-2 infection as compared to the general population 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
653 2 |a Adrenal Cortex Hormones  |6 D000305  |a therapeutic use  |6 Q000627 
653 2 |a Adult  |6 D000328 
653 2 |a Aged  |6 D000368 
653 2 |a Antibodies, Monoclonal, Humanized  |6 D061067  |a therapeutic use  |6 Q000627 
653 2 |a Antirheumatic Agents  |6 D018501  |a therapeutic use  |6 Q000627 
653 2 |a Autoimmune Diseases  |6 D001327  |a *complications  |6 Q000150  |a drug therapy  |6 Q000188 
653 2 |a Betacoronavirus  |6 D000073640 
653 2 |a Colchicine  |6 D003078  |a therapeutic use  |6 Q000627 
653 2 |a Coronavirus Infections  |6 D018352  |a *complications  |6 Q000150 
653 2 |a Cross-Sectional Studies  |6 D003430 
653 2 |a Female  |6 D005260 
653 2 |a Humans  |6 D006801 
653 2 |a Hydroxychloroquine  |6 D006886  |a therapeutic use  |6 Q000627 
653 2 |a Italy  |6 D007558 
653 2 |a Male  |6 D008297 
653 2 |a Middle Aged  |6 D008875 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a *complications  |6 Q000150 
655 7 |a COVID-19  |2 gnd 
655 7 |a Hydroxychloroquine  |2 gnd 
655 7 |a Immunosuppressants  |2 gnd 
655 7 |a Systemic autoimmune diseases  |2 gnd 
655 7 |a Tocilizumab  |2 gnd 
655 7 |a Adrenal Cortex Hormones  |2 gnd 
655 7 |a Antibodies, Monoclonal, Humanized  |2 gnd 
655 7 |a Antirheumatic Agents  |2 gnd 
655 7 |a Hydroxychloroquine  |2 gnd 
655 7 |a 4QWG6N8QKH  |2 gnd 
655 7 |a tocilizumab  |2 gnd 
655 7 |a I031V2H011  |2 gnd 
655 7 |a Colchicine  |2 gnd 
655 7 |a SML2Y3J35T  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a Hydroxychloroquine 
689 1 2 |a Immunosuppressants 
689 1 3 |a Systemic autoimmune diseases 
689 1 4 |a Tocilizumab 
689 1 |5 DE-601 
689 2 0 |a Adrenal Cortex Hormones 
689 2 1 |a Antibodies, Monoclonal, Humanized 
689 2 2 |a Antirheumatic Agents 
689 2 3 |a Hydroxychloroquine 
689 2 4 |A r  |a 4QWG6N8QKH 
689 2 5 |a tocilizumab 
689 2 6 |A r  |a I031V2H011 
689 2 7 |a Colchicine 
689 2 8 |A r  |a SML2Y3J35T 
689 2 |5 DE-601 
700 1 |a Bettiol, Alessandra 
700 1 |a Mattioli, Irene 
700 1 |a Silvestri, Elena 
700 1 |a Di Scala, Gerardo 
700 1 |a Urban, Maria Letizia 
700 1 |a Vaglio, Augusto 
700 1 |a Prisco, Domenico 
773 0 8 |i in  |t Autoimmunity reviews  |g Vol. 19, No. 7 (2020), p. 102575  |q 19:7<102575  |w (DE-601)NLM126100284  |x 1873-0183 
856 4 1 |u http://dx.doi.org/10.1016/j.autrev.2020.102575  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 19  |j 2020  |e 7  |b 04  |c 07  |h 102575